PCRX — Pacira Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $941.79m
- $1.08bn
- $726.41m
- 89
- 73
- 46
- 79
Annual cashflow statement for Pacira Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 42 | 15.9 | 42 | -99.6 | 7.03 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 69.8 | 62.2 | 67.3 | 208 | 85.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -25.5 | -16.4 | -45.8 | -18.5 | -38.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 126 | 145 | 155 | 189 | 152 |
| Capital Expenditures | -45.9 | -30.1 | -15.2 | -10.6 | -15.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 25.1 | -195 | 92.7 | -72.6 | 115 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -20.8 | -225 | 77.5 | -83.3 | 99.5 |
| Financing Cash Flow Items | -5.17 | 0 | -5.86 | -27.2 | -5.62 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 381 | -402 | -183 | 17.4 | -370 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 486 | -481 | 49.2 | 123 | -118 |